The COVID-19 pandemic has suddenly accelerated the shift of incorporating virtual or remote elements into traditional clinical trials. For sponsors currently using remote monitoring practices or for those looking to incorporate remote services and technologies, how will they safeguard patient safety and ensure data quality in today's current environment?

A large pharmaceutical company was initiating an effort to collect and analyze biomarker data from over 200 trials across three therapeutic areas. They sought a partner who could help them support all aspects of data management and provide clean, quality biomarker data in their standard format.

In this case study, a large global pharmaceutical company partnered with Labcorp FSPx to augment their clinical operations. This case study discusses how Labcorp FSPx helped the sponsor quickly hire 53 clinical research associates, despite the challenges of working during the COVID-19 outbreak.

This infographic educates on how identifying patients with specific genetic markers and linking them to trial sites can expand access to hard-to-find patient pools for faster enrollment of the right patients for precision medicine oncology trials.

This case study describes the key developments and milestones for breast cancer therapies and highlights how the Labcorp enterprise played pivotal roles in aiding these remarkable accomplishments.

This case study offers insights from multiple success stories of partnering with leading pharmaceutical companies to investigate and validate biomarkers, manage clinical trials and launch companion diagnostic assays for NSCLC.

Since the FDA and EMA released guidance on risk-based monitoring in 2013, implementation of the laid-out principles has matured into a RBQM approach. Widespread adoption of RBQM has been slow due to the persistent belief that trial quality can only be achieved with a high degree of source data verification (SDV) and recurring on-site monitoring visits.

Toxicol Pathol 2021.49:569-580 -- In all toxicology studies, the differentiation of microscopic findings induced by a test article from the spontaneous background findings that may occur in the tissues of a given species is critical.

Inspiring Science Scientific Acumen Rich Medical Expertise Committed Team of Therapeutic Area Specialists Patient-Centric Solutions Product Development Consulting Group Patient Intelligence Database Enterprise-Wide Excellence Biomarker Center of Excellence Integrated Services Cell and Gene Therapy

Nonalcoholic fatty liver disease (NAFLD) is defined by the accumulation of lipids in hepatocytes, in the absence of significant alcohol intake, viral infection, or other etiologies of fatty liver disease.